Furthermore, at an advanced stage of tumor development, TDLN- transitions from an immunoactivated to a TDLN+ immune tolerance state, as evidenced by a significantly lower concentration of IFN-γ in TDLN+ than in TDLN−28. This evidence concerns the gene IFNG and neoplasm.